{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T14:39:53Z","timestamp":1776609593975,"version":"3.51.2"},"reference-count":13,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/13543784.2023.2230118","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T08:25:56Z","timestamp":1687767956000},"page":"563-565","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["What is the progress of experimental drug development for fibromyalgia?"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5458-1897","authenticated-orcid":false,"given":"Kim","family":"Lawson","sequence":"first","affiliation":[{"name":"Department of Biosciences and Chemistry, Biomolecular Sciences Research Centre, Sheffield Hallam University, College of Health, Wellbeing & Life Sciences, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00506-w"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.5497\/wjp.v6.i1.1"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155330"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-015-0038-6"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871527318666190227205359"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.8220"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2092"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnab338"},{"key":"e_1_3_3_11_1","unstructured":"A proof-of-concept study to evaluate the efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome. 2023 Mar 10 cited 2023 Apr 5]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05643794"},{"issue":"18","key":"e_1_3_3_12_1","first-page":"295","article-title":"NYX-2925, a novel N-methyl-D-aspartate receptor positive allosteric-modulator, showed antinociceptive activity in functional neuroimaging evaluations correlated with improved patient reported pain and fibromyalgia symptoms (P1-4.001)","volume":"98","author":"Murck H","year":"2022","unstructured":"Murck H, Harte S, Larkin T, et al. NYX-2925, a novel N-methyl-D-aspartate receptor positive allosteric-modulator, showed antinociceptive activity in functional neuroimaging evaluations correlated with improved patient reported pain and fibromyalgia symptoms (P1-4.001). Neurol. 2022;98(18 Supplement):295.","journal-title":"Neurol"},{"key":"e_1_3_3_13_1","unstructured":"Evaluate the efficacy and safety of NYX-2925 in subjects with fibromyalgia. 2022 Sep 16 cited 2023 Apr 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03249103"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2020-101273"},{"key":"e_1_3_3_15_1","unstructured":"Open-label study to assess the safety and efficacy of TRP-8802 with psychotherapy in adult participants with fibromyalgia. 2021 Nov 19 cited 2023 Apr 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05128162"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2023.2230118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T07:02:44Z","timestamp":1710313364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2023.2230118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/13543784.2023.2230118"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2023.2230118","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}